+86-28-82633987
Product name: Bakuchiol
Synonym name:
Catalogue No.: BP0235
Cas No.: 10309-37-2
Formula: C18H24O
Mol Weight: 256.389
Botanical Source: Psoralea corylifolia, Psoralea drupacea, Psoralea glandulosa and Otholobium pubescens
Physical Description: Oil
Type of Compound: Phenols
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.
Descriptions:
Bakuchiol is isolated from the seeds of Psoralea corylifolia, a tree native to China with various uses in traditional medicine, it shows bactericidal effects against all bacteria tested, including S. mutans, Streptococcus sanguis, Streptococcus salivarius, Streptococcus sobrinus, Enterococcus faecalis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Actinomyces viscosus, and Porphyromonas gingivalis, with MICs ranging from 1 to 4 microg/ml and the sterilizing concentration for 15 min ranging from 5 to 20 microg/ml; furthermore, bakuchiol is also effective against adherent cells of S. mutans in water-insoluble glucan in the presence of sucrose and inhibited the reduction of pH in the broth; thus, bakuchiol would be a useful compound for development of antibacterial agents against oral pathogens and has great potential for use in food additives and mouthwash for preventing and treating dental caries.[1]
Bakuchiol analogs, especiallyΔ3,2-hydroxybakuchiol, are monoamine transporter inhibitors involved in regulating dopaminergic and noradrenergic neurotransmission and may have represented potential pharmacotherapies for disorders such as Parkinson's disease, depression, and cocaine addiction.[2]
Bakuchiol and Psoralea corylifolia L. (PCE) treatments reduce postmenopausal bone loss by increasing alkaline phosphatase, Ca concentrations, serum E2 concentration and bone mineral density, and by decreasing the inorganic P level, indicates that bakuchiol and PCE treatments could protect against bone loss.[3]
Bakuchiol is a phenolic isoprenoid with novel enantiomer-selective anti-Influenza A virus activity involving Nrf2 activation.[4]
Bakuchiol is a hepatoprotective compound of psoralea corylifolia on tacrine-induced cytotoxicity in Hep G2 cells.[5]
Bakuchiol derivatives are novel and potent cytotoxic agents.[6]
References:
[1] Katsura H, Tsukiyama R I, Suzuki A, et al.Antimicrob Agents Ch, 2001, 45(11):3009-13.
[2] Zhao G, Zang S Y, Zheng X W, et al. Biochem Pharmacol, 2008, 75(9):1835-47.
[3] Lim S H, Ha T Y, Kim S R, et al. Brit J Nut, 2009, 101(7):1031-9.
[4] Shoji M, Arakaki Y, Esumi T, et al. J Biol Chem, 2015, 290(46):28001-17.
[5] Cho H, Jun J Y, Song E K, et al. Planta Med, 2001, 67(8): 750-1.
[6] Majeed R, Reddy M V, Chinthakindi P K, et al. Eur J Med Chem, 2012, 49(1):55-67.
[7] Jeong M, Hong T, Lee K, et al. J Aoac Int, 2015, 98(4):902-6.
HPLC of Bakuchiol
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
20.2300
4.7000
4.5000
High
No
No
No
No
No
No
Bakuchiol (CAS No.: 10309-37-2), a natural plant estrogen, was first isolated from the seeds of the traditional Chinese medicine Psoralea corylifolia L. In recent years, with the deepening study of pharmacological activity of natural products, psoralen has attracted widespread attention due to its multi-target and multifunctional biological activity. It demonstrates significant potential in anti-inflammatory, antibacterial, anti-tumor, and drug metabolism regulation, especially in modulating hyperglycemia-related targets. In addition, psoralen has good druggability parameters and safety, laying a solid foundation for its clinical translation. This paper will systematically review the chemical structure, origins, pharmacological activity, mechanism of action, druggability, and clinical application prospects of psoralen, aiming to provide theoretical support and reference for related research and applications.
Psorol has a molecular formula of C18H24O and a molecular weight of 258.38, belonging to the monoterpene class of phenols. Its structural features include a phenolic hydroxyl group and a long-chain allyl side chain, giving it certain hydrophobicity and aromaticity. Its LogP value is about 4.7, indicating strong lipid solubility, which facilitates membrane penetration and distribution in vivo. Psoraleol has a topological surface area (TPSA) of 20.23 Ų and a hydrogen bond acceptor count of 1, indicating a relatively simple molecular structure and low polarity, which facilitates oral absorption and blood-brain barrier penetration. Pharmacological studies have shown that psoralen has high blood-brain barrier permeability, with no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibition. The Ames test result was negative, indicating a low genotoxicity risk and good safety.
Psoraleol mainly comes from Psoralea seeds, which are the dried mature seeds of the leguminous plant Psoralea corylifolia L. and are commonly used medicinal materials in traditional Chinese medicine. Psorol accounts for a high proportion of psoralea seeds, and its content is greatly influenced by growth environment, harvest time, and processing techniques.
In terms of extraction methods, traditional organic solvent extraction methods, such as ethanol or methanol extraction, combined with ultrasonic-assisted extraction or reflux extraction technologies, can effectively improve the extraction efficiency of psoralen. In recent years, supercritical CO2 extraction technology has gradually become a research hotspot for psoralen extraction due to its green and environmentally friendly nature, high efficiency, and strong selectivity. After extraction, purification is performed using silica gel column chromatography, high-performance liquid chromatography (HPLC), and other methods to ensure the acquisition of high-purity psulalen samples, meeting the needs of pharmacological research and formulation development.
Psorol has broad and diverse pharmacological activities, covering anti-inflammatory, antibacterial, anti-tumor, antioxidant, and drug metabolism regulation.
Psorol can significantly inhibit the production and release of inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and nitric oxide (NO). It regulates the nuclear factor κB (NF-κB) signaling pathway, suppressing the expression of pro-inflammatory genes and thereby reducing inflammatory responses. Both in vivo and in vitro experiments confirmed that psoralen exhibited good anti-inflammatory effects in inflammatory models, suggesting its potential application value in the treatment of inflammation-related diseases.
Psoraleol exhibits inhibitory effects on various bacteria and fungi, especially showing strong antibacterial activity against common pathogens such as Staphylococcus aureus, Escherichia coli, and Candida albicans. Its antibacterial mechanism may involve damaging cell membrane integrity, inhibiting cell wall synthesis, and interfering with cellular metabolic processes. The antibacterial properties of psoralen provide a theoretical basis for its development as a natural antimicrobial.
Psorol exhibits effects in various tumor cell lines by inhibiting cell proliferation, inducing apoptosis, and suppressing tumor metastasis. Research shows that psoralen exerts anti-tumor effects by regulating cyclins, activating mitochondrial apoptotic pathways, and inhibiting tumor-related signaling pathways (such as PI3K/Akt, MAPK). Additionally, psoralen can enhance the sensitivity of radiotherapy and chemotherapy, offering potential adjunctive therapeutic value.
Psoraleol has been confirmed as a non-competitive inhibitor of multiple enzymes, especially UDP-glucuronyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2), with IC50s of 40.9 μM and 7.28 μM, respectively. This suggests that psoralen may regulate drug biotransformation and clearance during drug metabolism, affecting drug efficacy and toxicity, suggesting its potential role in drug interactions and pharmacokinetic regulation.
The multi-target mechanism of psoralen forms the basis of its broad pharmacological activity. Research on hyperglycemia-related targets has been particularly prominent. Psoraleol can regulate the following key targets:
Psorol regulates these targets to comprehensively improve abnormal glucose metabolism and alleviate hyperglycemic symptoms. In addition, psoralen exerts anti-inflammatory and antitumor effects by modulating signaling pathways such as NF-κB, MAPK, and PI3K/Akt, demonstrating its multi-target and multi-pathway pharmacological characteristics.
The druggability parameters of psoralen indicate that it has promising potential for drug development. Moderate molecular weight (258.38) and high lipophilubility (LogP=4.7) facilitate oral absorption and cell membrane penetration. Low TPSA values (20.23 Ų) and the number of hydrogen bond receptors further support its good bioavailability and blood-brain barrier penetration ability.
Toxicological evaluation showed that psoralen showed no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibition. Ames-induced mutagenic tests were negative, indicating high safety and suitability for long-term use. Pharmacokinetic studies show that psoralen is rapidly absorbed orally and widely distributed, especially at high concentrations in the central nervous system, suggesting its potential for neurological diseases.
The inhibitory effect of psoralen on metabolic enzymes such as UGT2B7 and hCE2 suggests it may affect the metabolism of other drugs, and potential drug interactions should be monitored in clinical applications.
As a versatile natural product, psoralen has broad clinical application potential. In the treatment of hyperglycemia, it improves abnormal glucose metabolism by regulating multiple key targets, showing potential as a novel antidiabetic drug. At the same time, the anti-inflammatory, antibacterial, and antitumor activities of psoralen provide new ideas for its use in adjuvant treatment of inflammatory diseases, infections, and tumors.
In addition, Psorol's good safety and druggability provide assurance for its development of oral and topical formulations. Especially in the fields of dermatological treatment and beauty, psoralen has been widely used in anti-aging and skin repair products due to its estrogen-like activity and antioxidant properties.
Future research should focus on the clinical pharmacokinetics, dose optimization, and long-term safety evaluation of psoralen, combined with modern drug design techniques to develop structurally modified derivatives to enhance their activity and selectivity. Furthermore, in-depth analysis of its molecular mechanisms and multi-target synergistic effects will help promote the clinical translation of psoralen.
Psorol, as a natural plant estrogen with a clear source and unique structure, shows broad prospects for research and application thanks to its multi-target and multifunctional pharmacological activity. Its potential in anti-inflammation, antibacterial, anti-tumor, and hyperglycemia treatment, combined with its excellent druggability and safety, makes it an important research subject in the field of natural product pharmacology. In the future, as pharmacological mechanisms are further elucidated and clinical research advances, psoralen is expected to become an important candidate for the development of novel natural drugs, providing new strategies and means for the prevention and treatment of related diseases.
Shenshuai
Wenjing
Hedandan
